CureVac’s mRNA based Vaccine Candidate against SARS-CoV-2

Materials for discussion with EU APA group
July 27\textsuperscript{th}, 2020

- STRICTLY CONFIDENTIAL -
Key discussion topics for today

In our last discussion, we concluded with the following actions, agreeing for CureVac to come back to the EU APA team on the following topics:

1. Update of ongoing
2. How CureVac could
3. Clarify the
4. Clarify

In addition, CureVac would like **clarity on timelines to get to an agreement about an EU APA**. Indeed, at the CureVac is eager for Early clarity and commitment
1. CureVac’s SARS-CoV-2 Project: overview of the ongoing
Status of results support doses
As a result, CureVac is now in a position to - even at a level

450m europeans
300m vaccine regimens
600m doses

Clear priority populations

Health Care Workers
60+ years old
Chronic diseases

Manage supply risk
1. Across most promising vaccine modalities in clinical development:
   - Protein-based
   - Viral
   - mRNA
2. Across manufacturers: 200-400m doses each
3. Rationale for CureVac’s proposed pricing

- R&D and manufacturing ramp-up commitment of
- Besides the
- CureVac recently

Pricing reference points are emerging and CureVac’s offer compares favourably despite large subsidies to other manufacturers
Based on initial Europe Regimen doses; in million€

Price: 
Cost of goods: 
Program cost: 
Public funding: 
Investments to build CureVac mRNA platform since 2000:
CureVac bearing the development and manufacturing infrastructure risk

Pricing reference points are emerging
4. Context for EU APA milestones: plan
Key Project Milestones of interest in context of EU APA

<table>
<thead>
<tr>
<th>#</th>
<th>Milestone</th>
<th>Planned Date</th>
<th>Proposed upfront payment milestones</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td>Milestone 1</td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td>Milestone 2</td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td>Milestone 3</td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td>Milestone 4</td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Release of EU APA upfront payment milestones

* Without the ongoing 15m€ Ph1 for which CureVac received CEPI funding
** Additional GMP III manufacturing lines
Next steps

CureVac is a cutting-edge but mid-sized European biotech without the deep pockets of big pharma, nor the massive US BARDA grants that some manufacturers have received.

CureVac needs